Amgen Teams with Daiichi Sankyo on Biosimilars Deal

U.S.-based Amgen Inc. announced an exclusive agreement with Daiichi Sankyo for the commercialization of nine biosimilars in Japan including biosimilars of AbbVie’s Humira and Roche Holding's Avastin and Herceptin.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news